NCT06653348 Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
| NCT ID | NCT06653348 |
| Status | Recruiting |
| Phase | Phase 2, Phase 3 |
| Sponsor | Mazandaran University of Medical Sciences |
| Condition | Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-04-01 |
| Primary Completion | 2026-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 100 participants in total. It began in 2024-04-01 with a primary completion date of 2026-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 6 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.
Eligibility Criteria
Inclusion Criteria: * signing inform consent, * recent ischemic stroke within 24 h, * diagnosed by brain CT or MRI mild stroke with NIHSS =\<8 and no evidence of large infarct in brain imaging * high risk TIA with ABCD \>4, * no cardioembolic source such as low E/F, MS, AF ,... * no specific etiology such as dissection, vasculitis, ... * no carotid stenosis \> 50 % in side of involvement Exclusion Criteria: * history of hypersensitivity to consumptive drug * any indication for anticoagulant therapy * acute phase treatment with intravenous thrombolysis or thrombectomy * any contraindication for consumptive drug * history of intracranial hemorrhage * history of GI bleeding during past 6 m * candidate for endarterectomy * history of coagulopathy * active hemorrhagic diathesis during randomization
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06653348 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06653348 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06653348 currently recruiting?
Yes, NCT06653348 is actively recruiting participants. Contact the research team at athena.sharifi@yahoo.com for enrollment information.
Where is the NCT06653348 trial being conducted?
This trial is being conducted at Sari, Iran.
Who is sponsoring the NCT06653348 clinical trial?
NCT06653348 is sponsored by Mazandaran University of Medical Sciences. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.